Effectiveness of BNT162b2 vaccine against SARS-CoV-2 infection and severe COVID-19 in children aged 5–11 years in Italy: a retrospective analysis of January–April, 2022

BACKGROUND: By April 13, 2022, more than 4 months after the approval of BNT162b2 (Pfizer–BioNTech) for children, less than 40% of 5–11-year-olds in Italy had been vaccinated against COVID-19. Estimating how effective vaccination is in 5–11-year-olds in the current epidemiological context dominated b...

Descripción completa

Detalles Bibliográficos
Autores principales: Sacco, Chiara, Del Manso, Martina, Mateo-Urdiales, Alberto, Rota, Maria Cristina, Petrone, Daniele, Riccardo, Flavia, Bella, Antonino, Siddu, Andrea, Battilomo, Serena, Proietti, Valeria, Popoli, Patrizia, Menniti Ippolito, Francesca, Palamara, Anna Teresa, Brusaferro, Silvio, Rezza, Giovanni, Pezzotti, Patrizio, Fabiani, Massimo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Ltd. 2022
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9246475/
https://www.ncbi.nlm.nih.gov/pubmed/35780801
http://dx.doi.org/10.1016/S0140-6736(22)01185-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9246475/
https://www.ncbi.nlm.nih.gov/pubmed/35780801
http://dx.doi.org/10.1016/S0140-6736(22)01185-0

Ejemplares similares